Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia

Tareq Abuasab,1 Jacob Rowe,1– 3 Ariella Tvito1 1Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel; 2Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; 3Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technolog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abuasab T, Rowe J, Tvito A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	acute lymphoblastic leukemia monoclonal antibodies blinatumumab inotuzumab ozogamicin rituximab Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/128a4b37bd1b4581b134c475acda3442
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:128a4b37bd1b4581b134c475acda3442
record_format	dspace
spelling	oai:doaj.org-article:128a4b37bd1b4581b134c475acda34422021-12-02T19:06:31ZEmerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia1177-5491https://doaj.org/article/128a4b37bd1b4581b134c475acda34422021-10-01T00:00:00Zhttps://www.dovepress.com/emerging-monoclonal-antibody-therapy-for-the-treatment-of-acute-lympho-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Tareq Abuasab,1 Jacob Rowe,1– 3 Ariella Tvito1 1Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel; 2Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; 3Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, IsraelCorrespondence: Jacob Rowe Tel + 972-502063199Fax + 972-26555755Email rowe@jimmy.harvard.eduAbstract: The treatment of adults with ALL has undergone tremendous progress over the past 15 years. The advances have been particularly marked with B-lineage ALL. The development of bispecific antibodies directed against CD19 ushered in a new era in overcoming persistent minimal disease in newly diagnosed ALL patients as well as successfully treating those with relapsed disease. The immune-conjugates targeting CD22 have also had a similarly impressive role in improving the outcome in such patients. These advances are now being extended to frontline regimens for B-lineage ALL, including the Philadelphia-chromosome-positive subtype. Over the past decade, the development of chimeric antigen receptor T-cell therapy (CAR-T) has ushered in a new era, opening up hope when none was available for patients with particularly advanced disease. Such advances come at a considerable price for toxicity, which, however, are lessening with experience and the development of new agents to ameliorate some of the toxicities. Unfortunately, the progress for T-cell in ALL has lagged behind that of B-lineage ALL. Of late, however, there are preliminary results of potentially exciting data using monoclonal antibodies against CD38, in the form of daratumumab, and it is hoped that these will lead to an equally successful advance in the treatment of T-ALL. Despite all these advances, ALL in adults remains a formidable disease. While ongoing progress is being made, also in the therapy of older patients, we are still lagging behind the almost totally curative potential of current therapy for childhood ALL.Keywords: acute lymphoblastic leukemia, monoclonal antibodies, blinatumumab, inotuzumab ozogamicin, rituximabAbuasab TRowe JTvito ADove Medical Pressarticleacute lymphoblastic leukemiamonoclonal antibodiesblinatumumabinotuzumab ozogamicinrituximabMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 419-431 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute lymphoblastic leukemia monoclonal antibodies blinatumumab inotuzumab ozogamicin rituximab Medicine (General) R5-920
spellingShingle	acute lymphoblastic leukemia monoclonal antibodies blinatumumab inotuzumab ozogamicin rituximab Medicine (General) R5-920 Abuasab T Rowe J Tvito A Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
description	Tareq Abuasab,1 Jacob Rowe,1– 3 Ariella Tvito1 1Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel; 2Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; 3Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, IsraelCorrespondence: Jacob Rowe Tel + 972-502063199Fax + 972-26555755Email rowe@jimmy.harvard.eduAbstract: The treatment of adults with ALL has undergone tremendous progress over the past 15 years. The advances have been particularly marked with B-lineage ALL. The development of bispecific antibodies directed against CD19 ushered in a new era in overcoming persistent minimal disease in newly diagnosed ALL patients as well as successfully treating those with relapsed disease. The immune-conjugates targeting CD22 have also had a similarly impressive role in improving the outcome in such patients. These advances are now being extended to frontline regimens for B-lineage ALL, including the Philadelphia-chromosome-positive subtype. Over the past decade, the development of chimeric antigen receptor T-cell therapy (CAR-T) has ushered in a new era, opening up hope when none was available for patients with particularly advanced disease. Such advances come at a considerable price for toxicity, which, however, are lessening with experience and the development of new agents to ameliorate some of the toxicities. Unfortunately, the progress for T-cell in ALL has lagged behind that of B-lineage ALL. Of late, however, there are preliminary results of potentially exciting data using monoclonal antibodies against CD38, in the form of daratumumab, and it is hoped that these will lead to an equally successful advance in the treatment of T-ALL. Despite all these advances, ALL in adults remains a formidable disease. While ongoing progress is being made, also in the therapy of older patients, we are still lagging behind the almost totally curative potential of current therapy for childhood ALL.Keywords: acute lymphoblastic leukemia, monoclonal antibodies, blinatumumab, inotuzumab ozogamicin, rituximab
format	article
author	Abuasab T Rowe J Tvito A
author_facet	Abuasab T Rowe J Tvito A
author_sort	Abuasab T
title	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
title_short	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
title_full	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
title_fullStr	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
title_full_unstemmed	Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
title_sort	emerging monoclonal antibody therapy for the treatment of acute lymphoblastic leukemia
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/128a4b37bd1b4581b134c475acda3442
work_keys_str_mv	AT abuasabt emergingmonoclonalantibodytherapyforthetreatmentofacutelymphoblasticleukemia AT rowej emergingmonoclonalantibodytherapyforthetreatmentofacutelymphoblasticleukemia AT tvitoa emergingmonoclonalantibodytherapyforthetreatmentofacutelymphoblasticleukemia
_version_	1718377132231491584

Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia

Ejemplares similares